Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computa...
Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Approximately 10% of colorectal cancers harbor
BRAF
V600E
mutations, which constitutively activate the MAPK signaling pathway. We sought to determine whether ERK inhibitor (GDC-0994)-containing regimens may be of clinical benefit to these patients based on data from in vitro (cell line) and in vivo (cell- and patient-derived xenograft) stu...
Alternative Titles
Full title
Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5460205
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5460205
Other Identifiers
ISSN
2056-7189
E-ISSN
2056-7189
DOI
10.1038/s41540-017-0016-1
